Short Interest in Envoy Medical, Inc. (NASDAQ:COCH) Decreases By 25.8%

Envoy Medical, Inc. (NASDAQ:COCH) was the target of a large decline in short interest in June. As of June 30th, there was short interest totalling 22,700 shares, a decline of 25.8% from the June 15th total of 30,600 shares. Based on an average daily volume of 41,500 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.4% of the shares of the stock are sold short.

Envoy Medical Stock Performance

NASDAQ:COCH traded down $0.04 during mid-day trading on Monday, hitting $2.35. 455 shares of the stock traded hands, compared to its average volume of 225,088. Envoy Medical has a 52 week low of $0.75 and a 52 week high of $11.72. The firm’s 50 day moving average is $2.60 and its two-hundred day moving average is $3.19.

Envoy Medical (NASDAQ:COCH) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.13). The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.08 million. Research analysts predict that Envoy Medical will post -1.05 EPS for the current year.

Hedge Funds Weigh In On Envoy Medical

Several hedge funds have recently added to or reduced their stakes in the company. Weiss Asset Management LP bought a new position in Envoy Medical in the 4th quarter worth about $37,000. WealthTrust Asset Management LLC bought a new position in Envoy Medical in the 1st quarter worth about $44,000. Finally, Virtu Financial LLC bought a new position in Envoy Medical in the 1st quarter worth about $55,000. 8.59% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

COCH has been the topic of several recent research reports. Lake Street Capital upped their target price on shares of Envoy Medical from $3.00 to $6.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Ascendiant Capital Markets initiated coverage on shares of Envoy Medical in a research report on Monday, June 24th. They set a “buy” rating and a $8.50 target price on the stock.

Envoy Medical Company Profile

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.